Cargando…
Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
Renal cell carcinoma (RCC) is one of the most lethal genitourinary malignancies. Recently, there has been a paradigm shift in the management of advanced RCC. New targeted therapies including vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors have been devel...
Autores principales: | Shahani, Rohan, Kwan, Kevin G, Kapoor, Anil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108692/ https://www.ncbi.nlm.nih.gov/pubmed/21701620 |
Ejemplares similares
-
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017) -
A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)
por: Shah, Ruchitbhai, et al.
Publicado: (2019) -
A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting
por: Fishman, Mayer N., et al.
Publicado: (2015) -
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
por: Molina, Ana M., et al.
Publicado: (2013) -
Role of everolimus in the treatment of renal cell carcinoma
por: George, Saby, et al.
Publicado: (2009)